

ASX Announcement

24 August 2020

Ten US university hospitals now deploying GMV's Independent Diagnostic Testing Facilities (IDTF) platform

- Four additional hospitals now deploying IDTF services, taking total institutional deployments to ten
- Active patient enrolments are ongoing and increasing – August patient numbers expected to comfortably exceed July enrolments of 3,925 providing further confidence GMV will meet a three-fold increase in 2020 (2019: 27,496)
- Another seven hospitals have completed *evaluation* phase and near completion of *implementation* – deployment expected to commence throughout September
- GMV receives ~US\$175 to ~US\$750 in reimbursements per patient monitored depending on specific modality
- Three new sales representatives hired to increase footprint in US hospital sector and pursue other opportunities

Medical device, telehealth and medical Services company **G Medical Innovations (ASX: GMV)** ("**G Medical**" or the "**Company**") is pleased to report on the continued growth it has achieved through the US hospital sector. The Company advises that another four US university hospitals have deployed its Independent Diagnostic Testing Facilities (IDTF) platform and remote patient monitoring services, taking the total number of institutions in the *treatment* phase to ten.

Further, G Medical is please to update that an additional seven hospitals have completed the *evaluation* phase, and are currently finalising *Implementation* processes. The Company expects that this process will be completed in the coming weeks and all institutions will progress through to IDTF deployment (active patient enrolment and treatment).

Deploying IDTF services to ten university hospitals is a major achievement for G Medical and will lead to a further increase in patient numbers and revenue. Since initial deployments with university hospitals (refer ASX announcement: 16 July 2020), G Medical has witnessed a significant increase in patient enrolments. During July, G Medical monitored 3,925 patients through its IDTF platform, with 2,275 being received from six partners in the early stage of the *treatment* phase. The Company anticipates that patient numbers will significantly increase in August and the coming months.




Table 1: Patients monitored through IDTF services on a monthly basis (January 2020 – July 2020)

G Medical expects to receive between ~US\$175 and ~US\$750 per patient monitored via reimbursements from insurers (i.e. Medicare), with the variance based on the specific modality and duration, including; AECG patch, Mobile Cardiac

Telemetry (MCT), Cardiac Event Monitoring (CEM). Additional revenue can be earned from potential sales channel for G Medical's FDA approved Prizma and GMP Patch devices.

G Medical's IDTF operations provide the Company with a dependable and highly scalable revenue generating platform. Based on sales and ongoing business development efforts, G Medical is confident of meeting its three-fold increase in patient monitoring numbers by the end of CY2020 (CY2019: 27,946 patients monitored).

To underpin additional business development initiatives and pursue other opportunities in the US hospital sector, G Medical has also expanded its US sales force, adding an additional three sales representatives. These individuals will target other US university hospitals that may benefit from IDTF deployment, potentially adding more patient enrolments.

CEO Dr Yacov Geva, said: *"The uptake that we are witnessing of our IDTF platform in the US hospital sector is excellent. We are confident that these new deployments will add to the growing patient enrolments we are witnessing from initial partners, providing G Medical with further diversified, stable revenue."*

"Telehealth services in the US continue to gain massive traction and G Medical is well positioned to capitalise on this trend. The addressable market for our remote patient monitoring services is currently valued at US\$6.61Bn and is expected to grow to over US\$17Bn by 2026¹. This highlights the considerable upside potential that G Medical can pursue through its established infrastructure and reliable service offering in the near future."

"Very soon, we will introduce complementary service offerings to our US hospital partners which will further augment and grow revenue streams for the Company. Further detail will be provided on these initiatives shortly."

Three phase approach to IDTF platform deployment with United States university hospitals:

Evaluation:	Implementation:	Treatment:
<ul style="list-style-type: none"> Identify university hospitals and medical institutions that institutions that would benefit from cardiac monitoring technologies and services, provided through G Medical's IDTF operations. Commence discussions with a number of management personnel at a number of hospitals is ongoing. Demonstrations of G Medical's IDTF platform and medical devices with management, institutional physicians and staff. Decision is made by hospital management to implement G Medical's IDTF platform. 	<ul style="list-style-type: none"> Ongoing education, training, and support services for institutional physicians and staff. Cyber security protocols and implementation in conjunction with in-hospital IT departments. Implementation of G Medical's 'applications' into organisation mainframes. G Medical's 'Home Connect' set-up and deployment. Data management, diagnostic and related protocols. Patient selection, enrolment, medical device deployment and management protocols set. 	<ul style="list-style-type: none"> Patient enrolments commence from hospital and individualised monitoring service (24 hours to 30 days or longer) commences. G Medical to receive between US\$[value] and US\$[Value] per patient monitored, plus a daily service fee – revenue to be booked within 90 days of enrolment. Services can include Mobile Cardiac Telemetry (MCT), Holter Monitoring and Ambulatory electrocardiography (AECG). Deployment allows for improved revenue for partner hospital and better patient care. R&D and business development work continues to broaden service offering, enhance protocols, improve efficiency and expand hospital staff knowledge base. <ul style="list-style-type: none"> Build sustainable infrastructure within Institutional partners; Medical device inventory management; Broadened direct and remote patient monitoring services; Improved cardiac rhythm disturbance protocols; Improved protocols for the placement of 'Cardiac Event Monitors' post Transcatheter aortic valve replacement (TAVR), and other procedures.

Ends

Authorised for release by Yacov Geva, Managing Director.

For more information, please contact:

Brendan De Kauwe
Director
Brendan@gmedinnovations.com

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.

ⁱ <https://www.polarismarketresearch.com/industry-analysis/us-telemedicine-market>